Rifampicin adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Rifampicin
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Also reported as: Rifampicin Capsules

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to September 2021, FDA received 6,406 adverse event reports that name Rifampicin. In these reports the drug is a suspect or interacting product.

In the same period, 2,633 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 0 reports in the 12 months to June 2026 and 0 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Rifampicin is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

FDA received no report that names Rifampicin in April to June 2026, in January to March 2026 or in April to June 2025.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 614 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 6,396 of the 6,406 reports (99.8%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 614 terms.

Reaction terms in the reports that name Rifampicin, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 6,406 reports
Drug interactionan interaction between medicines	883	13.8%
Pyrexiafever	579	9%
Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement	440	6.9%
Drug-induced liver injury	422	6.6%
Drug ineffectivethe medicine did not work as expected	374	5.8%
Paradoxical drug reaction	298	4.7%
Vomitingbeing sick	298	4.7%
Jaundiceyellowing of the skin or eyes	284	4.4%
Condition aggravatedthe condition being treated got worse	274	4.3%
Acute kidney injurysudden loss of kidney function	260	4.1%
Nauseafeeling sick	260	4.1%
Drug resistance	221	3.4%
Thrombocytopenialow platelets	205	3.2%
Rashskin rash	195	3%
Hepatotoxicityliver injury	187	2.9%
Dyspnoeashortness of breath	167	2.6%
Eosinophilia	163	2.5%
Hepatic failureliver failure	159	2.5%
Acute hepatic failure	156	2.4%
Tuberculosis	155	2.4%
Pruritusitching	148	2.3%
Alanine aminotransferase increasedraised liver enzyme (ALT)	145	2.3%
Off label useused for a purpose or in a way not on the label	144	2.2%
Hepatitis	140	2.2%
Drug level decreaseda low blood level of the medicine	126	2%
Rash maculo-papulara rash of flat and raised spots	124	1.9%
Malaisegeneral feeling of being unwell	122	1.9%
Aspartate aminotransferase increasedraised liver enzyme (AST)	120	1.9%
Anaemialow red blood cells	119	1.9%
Diarrhoealoose or frequent stools	117	1.8%
Decreased appetitereduced appetite	115	1.8%
Abdominal painstomach or belly pain	113	1.8%
Treatment failurethe treatment did not work	112	1.7%
Lymphadenopathyswollen lymph nodes	111	1.7%
Hepatic function abnormal	104	1.6%
Product use in unapproved indicationused for a purpose not on the label	103	1.6%
Astheniaweakness or lack of energy	102	1.6%
Liver function test abnormal	101	1.6%
Pulmonary tuberculosis	101	1.6%
Renal failurekidney failure	99	1.5%
Deaththe patient died; cause not stated by this term	98	1.5%
Transaminases increased	97	1.5%
Hepatic enzyme increasedraised liver enzymes	94	1.5%
Erythemaskin redness	92	1.4%
Renal impairmentreduced kidney function	90	1.4%
Sepsisa severe body-wide response to infection	88	1.4%
Hypotensionlow blood pressure	87	1.4%
Pleural effusionfluid around the lung	87	1.4%
Toxicity to various agentspoisoning or toxic effect of one or more substances	87	1.4%
Blood creatinine increasedraised creatinine, a kidney test	85	1.3%

Download all 614 terms of Rifampicin (CSV)

The counts add to more than 6,406 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Rifampicin with a page, in the order generic names, brand names, names as reported
Name	Name type	Reports
Rifampicin (this page)	Generic name	6,406
Rifadin	Brand name	929

Sum of the separately reported names: 7,335. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Rifampicin, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2004	77	77	13	11	47	10	0	36	0
2005	110	109	15	6	49	2	0	54	1
2006	99	99	23	17	61	4	0	30	0
2007	112	112	17	11	42	2	2	58	0
2008	108	107	16	21	68	1	4	35	1
2009	111	106	23	9	54	5	2	57	5
2010	140	138	26	6	71	2	0	72	2
2011	151	150	17	13	82	4	2	78	1
2012	232	229	23	14	99	1	0	152	3
2013	363	360	58	6	168	6	0	212	3
2014	383	379	98	20	149	2	1	265	4
2015	504	488	148	21	152	9	4	296	16
2016	504	480	54	49	180	16	1	335	24
2017	658	653	108	52	273	1	6	463	5
2018	781	772	111	75	360	8	0	545	9
2019	815	791	93	41	327	10	1	610	24
2020	737	709	73	49	346	18	2	517	28
2021	521	516	68	38	259	8	1	378	5

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Rifampicin, by the year in which FDA received them

Show the figures of the chart as a table

Reports that name Rifampicin, by the year in which FDA received them
Year	Reports
2004	67
2005	101
2006	119
2007	108
2008	115
2009	113
2010	148
2011	162
2012	259
2013	380
2014	374
2015	513
2016	533
2017	680
2018	790
2019	796
2020	719
2021	426

Reports that name Rifampicin, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Rifampicin
Age	Reports	Share
Under 2	93	1.5%
2 to 11	207	3.2%
12 to 17	177	2.8%
18 to 44	1,554	24.3%
45 to 64	1,334	20.8%
65 to 74	809	12.6%
75 and over	772	12.1%
Age not given	1,460	22.8%

Sex of the patient in the reports that name Rifampicin
Sex	Reports	Share
Female	2,345	36.6%
Male	2,989	46.7%
Unknown or not given	1,072	16.7%

Type of reporter in the reports that name Rifampicin
Reporter	Reports	Share
Physician	1,511	23.6%
Pharmacist	344	5.4%
Other health professional	3,933	61.4%
Lawyer	0	0%
Consumer or non-health professional	294	4.6%
Not given	324	5.1%

Age and sex are as the report gives them. The reporter is the primary source in the report. 10.6% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Rifampicin record
Indication as recorded (MedDRA)	Reports	Share
Tuberculosis	1,417	22.1%
Pulmonary tuberculosis	782	12.2%
Disseminated tuberculosis	184	2.9%
Staphylococcal infection	106	1.7%
Endocarditis	89	1.4%
Mycobacterium avium complex infection	71	1.1%

The reporter fills in the indication, and the field is often empty. Each share is of all 6,406 reports.

Drugs in the same reports

Other drugs that the reports of Rifampicin name, in any role, in order of name
Drug	Reports that name the two
Ciprofloxacin	290
Clarithromycin	371
Ethambutol	2,237
Isoniazid	2,860
Levofloxacin	482
Linezolid	260
Moxifloxacin	228
Prednisolone	313
Pyrazinamide	2,342
Vancomycin	516

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Rifadin same ingredient
Rifadine next in the A to Z list
Rifampicine next in the A to Z list
Rifampin next in the A to Z list
Rifabutin next in the A to Z list
Rifapentine next in the A to Z list
Ribomustin next in the A to Z list
Rifater next in the A to Z list
Riboflavin next in the A to Z list
Rifaximin next in the A to Z list
Ribociclib next in the A to Z list
Rifinah next in the A to Z list

These links are for navigation. No count selected them.

Official pages

DailyMed labels for RifampicinThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Rifampicin: adverse event reports that FDA received. https://reportedreactions.com/drug/rifampicin/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Rifampicin as a suspect or interacting product. The 2,633 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Rifampicin was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Rifampicin?

No. It is a count of what people reported to FDA: 6,406 reports from January 2004 to September 2021. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Other health professional (61.4%), physician (23.6%) and pharmacist (5.4%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page